摘要: The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Although many benefit from in adjuvant and metastatic settings, resistance an important clinical problem. target of vivo ER. Over last decade advances have been made our understanding biology ER which may help to explain how develops. Such mechanisms include changes expression ERalpha or ERbeta, alterations co-regulatory proteins, influences cellular kinase signal transduction pathways. experimental evidence supporting these are discussed this review.
bioscientifica.com
core.ac.uk
endocrinology-journals.org参考文章(109)
G. Bunone, P. A. Briand, R. J. Miksicek, D. Picard, Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. The EMBO Journal. ,vol. 15, pp. 2174- 2183 ,(1996) , 10.1002/J.1460-2075.1996.TB00571.X
CD Wallace, RJ Baumann, EA Cashman, JA Dumont, AJ Bitonti, DE Cross-Doersen, Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth & Differentiation. ,vol. 7, pp. 351- 359 ,(1996)
Helmut Dotzlaw, Leigh C. Murphy, Peter H. Watson, Etienne Leygue, Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Research. ,vol. 59, pp. 1175- 1179 ,(1999)
Rachel Schiff, C. Kent Osborne, Jiang Shou, Suzanne A.W. Fuqua, Estrogen Receptor: Current Understanding of Its Activation and Modulation Clinical Cancer Research. ,vol. 7, pp. 4338- 4342 ,(2001)
Tommaso Simoncini, Ali Hafezi-Moghadam, Derek P. Brazil, Klaus Ley, William W. Chin, James K. Liao, Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase Nature. ,vol. 407, pp. 538- 541 ,(2000) , 10.1038/35035131
S. R. Ebbs, S. R. D. Johnston, J. Salter, J. Newby, I. E. Smith, G. Saccani-Jotti, M. Coppen, M. Dowsett, Changes in Estrogen Receptor, Progesterone Receptor, and pS2 Expression in Tamoxifen-resistant Human Breast Cancer Cancer Research. ,vol. 55, pp. 3331- 3338 ,(1995)
Carlos L. Arteaga, Hirokazu Kurokawa, Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clinical Cancer Research. ,vol. 7, pp. 4436- 4442 ,(2001)
I A Jaiyesimi, A U Buzdar, D A Decker, G N Hortobagyi, Use of tamoxifen for breast cancer: twenty-eight years later. Journal of Clinical Oncology. ,vol. 13, pp. 513- 529 ,(1995) , 10.1200/JCO.1995.13.2.513
Donald A. Berry, Hyman B. Muss, Ann D. Thor, Lynn Dressler, Edison T. Liu, Gloria Broadwater, Dan R. Budman, I. Craig Henderson, Maurice Barcos, Daniel Hayes, Larry Norton, HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer Journal of Clinical Oncology. ,vol. 18, pp. 3471- 3479 ,(2000) , 10.1200/JCO.2000.18.20.3471
Santo V. Nicosia, June E. Paciga, Richard I. Feldman, Mei Sun, Jin Q. Cheng, Domenico Coppola, Sue A. Shelley, You Yong Lu, Zeng-qiang Yuan, Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Research. ,vol. 61, pp. 5985- 5991 ,(2001)